The B7 family and cancer therapy: Costimulation and coinhibition Journal Article


Authors: Zang, X.; Allison, J. P.
Article Title: The B7 family and cancer therapy: Costimulation and coinhibition
Abstract: The activation and development of an adaptive immune response is initiated by the engagement of a T-cell antigen receptor by an antigenic peptide-MHCcom plex. The outcome of this engagement is determined by both positive and negative signals, costimulation and coinhibition, generated mainly by the interaction between the B7 family and their receptor CD28 family. The importance of costimulation and coinhibition of T cells in controlling immune responses is exploited by tumors as immune evasion pathways. Absence of the expression of costimulatory B7 molecules renders tumors invisible to the immune system, whereas enhanced expression of inhibitory B7 molecules protects them from effective T cell destruction. Therefore, the manipulation of these pathways is crucial for developing effective tumor immunotherapy. Translation of our basic knowledge of costimulation and coinhibition into early clinical trials has shown considerable promise. © 2007 American Association for Cancer Research.
Keywords: unclassified drug; clinical trial; review; clinical trials as topic; neoplasms; antigen expression; t-lymphocytes; animals; mice; glycoprotein gp 100; interleukin 2; ipilimumab; cancer immunotherapy; epidermal growth factor receptor 2; protein; t lymphocyte receptor; lymphocyte activation; cancer vaccines; mammalian target of rapamycin; malignant neoplastic disease; antigens, cd; estrogen receptor; progesterone receptor; tumor cell vaccine; adaptive immunity; cytotoxic t lymphocyte antigen 4; granulocyte macrophage colony stimulating factor vaccine; major histocompatibility complex; cd28 antigen; antigens, cd28; b7 antigen; cd86 antigen; antigens, differentiation; protein pd l1; antigens, cd80; tumor immunology; cp 675206
Journal Title: Clinical Cancer Research
Volume: 13
Issue: 18
ISSN: 1078-0432
Publisher: American Association for Cancer Research  
Date Published: 2007-09-15
Start Page: 5271
End Page: 5279
Language: English
DOI: 10.1158/1078-0432.ccr-07-1030
PUBMED: 17875755
PROVIDER: scopus
DOI/URL:
Notes: --- - "Cited By (since 1996): 78" - "Export Date: 17 November 2011" - "CODEN: CCREF" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Xingxing Zang
    14 Zang
  2. James P Allison
    130 Allison